Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596974 | 0.86 | TGFBR1 (0.47) | TGFBR1CYP3A4CYP2C8 | |
| SCHEMBL22270336 | 0.84 | TGFBR1 (0.50) | TGFBR1CYP3A4CYP2C8CYP1A2HTR2B | |
| SCHEMBL27006855 | 0.78 | CYP3A4 (0.40) | TGFBR1CYP3A4CYP2C8HTR2BIDO1 | |
| SCHEMBL30425007 | 0.78 | CYP3A4 (0.40) | TGFBR1CYP3A4CYP2C8HTR2BIDO1 | |
| SCHEMBL458804 | 0.77 | CYP3A4 (0.47) | CYP3A4CYP1A2 | |
| SCHEMBL28996713 | 0.77 | TGFBR1 (0.53) | TGFBR1CYP3A4CYP2C8ACVR1BIDO1 | |
| SCHEMBL30499257 | 0.77 | TGFBR1 (0.53) | TGFBR1CYP3A4CYP2C8ACVR1BIDO1 | |
| SCHEMBL25131726 | 0.74 | SCN9A (0.41) | TGFBR1CYP3A4HTR2BIDO1 | |
| SCHEMBL30226529 | 0.74 | SCN9A (0.41) | TGFBR1CYP3A4HTR2BIDO1 | |
| SCHEMBL2596874 | 0.74 | DPP4 (0.39) | TGFBR1CYP3A4CYP2C8CYP1A2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073918-B2 | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | ALK, ALKBH5, ALKBH3 | TGFBR1 413/4885CYP3A4 65/4885CYP2C8 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.